Issue #9 May 2021 • 2 minute read

Welcome to VITALITY.

You’re receiving this newsletter because you’re a customer, partner, or you’ve otherwise subscribed or opted in at one of our events, conferences, or website


  • Note from our CEO, Craig Cooper.
  • CardieX launches CONNEQT consumer brand.
  • May corporate update.
  • New US patent granted.

From the Heart

Thoughts from our CEO, Craig Cooper


We are kicking this summer off with a bang, not only did we launch our exciting new CONNEQT consumer brand, but the company also announced our May Corporate Update and a new US patent.

Check out the CONNEQT news on the big screen in Times Square – and read on for how you can sign up for updates.

Stay healthy, stay strong,


CardieX Launches CONNEQT Consumer Brand


Last week CardieX announced that ATCOR Medical will separate into two companies – ATCOR and CONNEQT. CONNEQT will focus on consumer wearables and home health devices, whereas ATCOR will continue to focus on medical devices and SaaS solutions for hospital, research and pharma, and specialized clinical markets.

For details on CONNEQT, check out CardieX CEO, Craig Cooper’s interview with Stockhead, this article in Fierce Biotech and the press release. Sign up for updates and follow CONNEQT on Twitter or Instagram.

May Corporate Update


In addition to the CONNEQT news, the company posted its May Corporate Update to the ASX featuring all the details on new product launches as well as market and sales updates. Click here to read the full presentation.

Welcome New Team Members


Last week, CardieX was granted a new US patent (USPTO 11,006,842) for the measurement of central blood pressure waveforms using a brachial blood pressure cuff, “Non-Invasive Brachial Blood Pressure Measurement.” The new patent will remain in force until 2038. The company now holds more than 14 patents in blood pressure and wearable sensor technologies which are being incorporated into their new CONNEQT devices.

Get In Touch


We’d love to hear from you

About Us

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company’s ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the CONNEQT brand, the company also develops consumer health wearables and devices as well as digital solutions. CardieX is listed on the Australian Stock Exchange (ASX:CDX).